Ucb UCB.BE | BRUSSELS Exch | Medical-Diversified | MktCap €38.38B Sales €6.85B | Shares 195M Float 99M

3225599999 ucb.com Brussels, BELGIUM Inc 1925 MGMT owns --
EPS Rank 78

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium. LESS

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS EUR	2.88	3.99	4.20	4.23	3.87	5.60	2.20	1.81	5.61
CASH FLOW/SHR EUR	1.85	4.64	5.44	4.40	5.20	7.67	5.36	3.16	5.56
PRETAX MARGIN %	18%	22%	22%	20%	16%	21%	9%	8%	19%
RETURN ON EQUITY %	10%	13%	13%	12%	10%	14%	5%	4%	11%
SALES % CHANGE	7%	9%	2%	6%	9%	8%	-5%	-5%	17%
SALES (MIL) EUR	4,147	4,530	4,632	4,913	5,347	5,777	5,517	5,252	6,152
WEEKLY	**Jun 27**	**Jul 4**	**Jul 11**	**Jul 18**	**Jul 25**	**Aug 1**	**Aug 8**	**Aug 15**	**Aug 22**
DATAGRAPH RATING	57	55	59	66	64	66	64	69	68
AVG DAILY VOL (000)	260	250	235	221	216	227	211	203	203
UP DOWN VOLUME	1.7	1.4	1.3	1.6	1.6	1.8	1.5	1.4	1.5
ACCUM/DIST RATING	15	15	21	24	31	34	33	31	36
RELATIVE STRENGTH	56	59	70	77	64	63	64	80	78
GROUP RANK	42	42	43	41	39	30	29	23	22

2025 Estimate	2026 Estimate
7.07 26%	9.72 37%

Earnings Growth Rate	Sales Growth Rate
2023-25 25% (69 Stability)	5%
2021-25 -7% (65 Stability)	3%

COMP RATING 96 SMR RATING A
INV T/O 1.7x 38

DEBT % 2022-24	29%	33%	30%
TAX RATE 2022-24	18%	22%	8%
BACKLOG 2022-24	--	--	--

R & D 28.90% BK VAL 3.74x '24
DIV EUR 0.97 (0.5%) DIV GR RT+2% (0)
BETA 1.55(44.00) ALPHA 0.00 (0.00)
2024 EMPLOYEES 9,378 (3%)

Europe Long +3.60% in 3.1 WKS

OH -4%

LOG (Fixed) PRICE

EPS 25 x

197.30 EUR
+4.80 +2.49%

7.01

78
A-

LOG VOLUME

2M

724.2K
-29%

FINANCIALS	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25
EPS (EUR)		3.02		2.58		2.10		0.10		1.64		0.17		1.10		4.51		2.50		3.77e
EPS % CHANGE		+57%		+32%		-30%		-96%		-22%		+70%		-33%		+2,553%		+127%		-16%e
SALES (MIL EUR)		2,778.0		2,999.0		2,925.0		2,592.0		2,589.0		2,663.0		2,791.0		3,361.0		3,487.0		3,708.3e
SALES % CHANGE		+7%		+9%		+5%		-14%		-11%		+3%		+8%		+26%		+25%		+10%e
EPS % SURPRISE		+11.5%		+17.2%		-16.4%		+61.6%		+55.9%		+16.4%		+18.6%		+10.6%		+6.8%		
FUNDS	1,369	1,379	1,392	1,392	1,470	1,581	1,415	1,403	1,390	1,387	1,432	1,464	1,474	1,591	1,698	1,828	1,825	1,831		
SHARES HELD BY FUNDS	53M	55M	56M	57M	56M	56M	54M	54M	53M	53M	54M	53M	58M	61M	62M	62M	60M	58M		

P/E	28
2025 Est.:	27.9
2026 Est.:	20.3
5-yr High:	111
5-yr Low:	15
vs Ind. Avg:	1.1x